Relay Therapeutics(RLAY) - 2025 Q3 - Quarterly Results

Exhibit 99.1 Relay Therapeutics Reports Third Quarter 2025 Financial Results and Corporate Updates Continued focused execution of RLY-2608 clinical trials in PI3Kα-mutated breast cancer and vascular malformations Appointed Lonnel Coats and Habib Dable, former biotech CEOs with launch and commercialization expertise, to the Company's Board of Directors Approximately $596 million in cash, cash equivalents and investments at end of Q3 2025 Cambridge, Mass. – November 6, 2025 – Relay Therapeutics, Inc. (Nasdaq: ...